Impact of KEAP1/NFE2L2 Mutations on Local Recurrence in Patients Receiving Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases

被引：0
|
作者：
Chen, M. S. [1 ]
Carpenter, D. J. [2 ]
Leng, J. X. [1 ]
Qazi, J. J. [1 ]
Wan, Z. [3 ]
Niedzwiecki, D. [3 ]
Alder, L. R. [4 ]
Clarke, J. [4 ]
Kirkpatrick, J. P. [1 ,5 ]
Floyd, S. R. [1 ]
Reitman, Z. J. [1 ]
Mullikin, T. C. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA
[2] Wellstar Paulding Hosp, Hiram, GA USA
[3] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA
[4] Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC USA
[5] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2498
引用
收藏
页码：E223 / E223
页数：1
相关论文
共 50 条
  • [1] Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer
    Jeong, Youngtae
    Hellyer, Jessica A.
    Stehr, Henning
    Hoang, Ngoc T.
    Niu, Xiaomin
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Neal, Joel W.
    Wakelee, Heather
    Diehn, Maximilian
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 274 - 281
  • [2] KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
    Binkley, Michael S.
    Jeon, Young-Jun
    Nesselbush, Monica
    Moding, Everett J.
    Nabet, Barzin
    Almanza, Diego S.
    Yoo, Christopher
    Kurtz, David Matthew
    Owen, Susie Grant
    Backhus, Leah Monique
    Berry, Mark F.
    Shrager, Joseph B.
    Ramchandran, Kavitha
    Padda, Sukhmani Kaur
    Das, Millie
    Neal, Joel W.
    Wakelee, Heather A.
    Alizadeh, Ash A.
    Loo, Billy W.
    Diehn, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
    Zhu, Hongyuan
    Yu, Yunfang
    Zheng, Yating
    Xu, Bin
    Zheng, Shaopeng
    Zeng, Fanjun
    Xie, Wenzhuan
    Huang, Luyu
    Li, Fasheng
    Lin, Weihuan
    Liao, Guoqing
    Wu, Shaowei
    Liu, Xinyi
    Huang, Mengli
    Zhou, Haiyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
    Paik, Paul K.
    Ahn, Linda Su Hyun
    Plodkowski, Andrew J.
    Fan, Pang-Dian
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC)
    Frank, R.
    Scheffler, M.
    Michels, S.
    Eisert, A.
    Fischer, R.
    Koenig, K.
    Merkelbach-Bruse, S.
    Serke, M.
    Ko, Y. D.
    Gerigk, U.
    Geist, T.
    Heukamp, L.
    Buettner, R.
    Wolf, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S645 - S645
  • [6] KEAP1-Mutations and NFE2L2-Mutations in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Frank, Rieke
    Scheffler, Matthias
    Michels, Sebastian
    Eisert, Anna
    Fischer, Rieke N.
    Koenig, Katharina
    Merkelbach-Bruse, Sabine
    Serke, Monika H.
    Ko, Yon-Dschun
    Gerigk, Ulrich
    Geist, Thomas
    Heukamp, Lukas C.
    Buettner, Reinhard
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S215 - S215
  • [7] KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC)
    Frank, R.
    Scheffler, M.
    Michels, S.
    Eisert, A.
    Gogl, L.
    Fischer, R.
    Koenig, K.
    Merkelbach-Bruse, S.
    Serke, M.
    Ko, Y. -D
    Gerigk, U.
    Geist, T.
    Heukamp, L.
    Buettner, R.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 268 - 268
  • [8] Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer
    Hellyer, Jessica A.
    Stehr, Henning
    Das, Millie
    Padda, Sukhmani K.
    Ramchandran, Kavitha
    Neal, Joel W.
    Diehn, Maximilian
    Wakelee, Heather A.
    LUNG CANCER, 2019, 134 : 42 - 45
  • [9] KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials
    Zhu, Hongyuan
    Xie, Daipeng
    Yu, Yunfang
    Yao, Lintong
    Xu, Bin
    Huang, Luyu
    Wu, Shaowei
    Li, Fasheng
    Zheng, Yating
    Liu, Xinyi
    Xie, Wenzhuan
    Huang, Mengli
    Li, Hao
    Zheng, Shaopeng
    Zhang, Dongkun
    Qiao, Guibin
    Chan, Lawrence W. C.
    Zhou, Haiyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC
    Arolt, Christoph
    Dugan, Margaret
    Wild, Robert
    Richartz, Vanessa
    Holz, Barbara
    Scheel, Andreas H.
    Braegelmann, Johannes
    Wagener-Ryczek, Svenja
    Merkelbach-Bruse, Sabine
    Wolf, Juergen
    Buettner, Reinhard
    Catanzariti, Luigi
    Fler, Matthias Schef
    Hillmer, Axel M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : 1550 - 1567
12345